Dashboard
Manage Tickers

TAK TAKEDA PHARMACEUTICAL CO LTD

NYSE takeda.com


$ 13.76 $ 0.01 (0.07 %)    

Monday, 13-Oct-2025 19:59:33 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 595.46 $ 0.00 (0 %)
DIA $ 458.67 $ 0.00 (0 %)
SPY $ 657.63 $ 0.00 (0 %)
TLT $ 91.12 $ 0.00 (0 %)
GLD $ 380.73 $ 0.00 (0 %)
$ 13.72
$ 13.74
$ 13.73 x 1,300
$ 14.60 x 10
-- - --
$ 12.80 - $ 15.69
2,456,696
na
23.28B
$ 0.30
$ 32.34
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report
Johnson & Johnson In Talks To Acquire Prot...
10/10/2025 17:06:05

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

whats-going-on-with-nano-cap-galecto-stock-on-tuesday
What's Going On With Nano-Cap Galecto Stoc...
10/07/2025 17:05:49

Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and cli...

reported-earlier-takeda-expands-global-csr-program-to-537m-beneficiaries-with-jpy-46b-commitment-across-94-countries
Reported Earlier, Takeda Expands Global CS...
09/24/2025 06:38:22

takeda-vela-to-transport-products-between-europe-us-using-sailing-cargo-trimaran
Takeda, VELA To Transport Products Between...
09/16/2025 12:16:50

takeda-reports-results-from-firstlight-and-radiantlight-studies-showing-oveporexton-improves-wakefulness-cataplexy-severity-and-quality-of-life
Takeda Reports Results From FirstLight And...
09/08/2025 07:25:42

– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025–...

on-friday-fda-approved-takedas-supplemental-application-for-vonvendi-expanding-the-indication-to-include-routine-prophylaxis-to-reduce-the-frequency-of-bleeding-episodes-in-adults-with-von-willebrand-disease
On Friday, FDA Approved Takeda's Supplemen...
09/07/2025 16:27:32

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (...

Core News & Articles
Novavax Receives Milestone Payment From Ta...
09/04/2025 12:10:22

takeda-canada-announces-fruzaqlatm-will-now-be-reimbursed-by-ramq-in-quebec
Takeda Canada Announces FRUZAQLATM Will No...
08/28/2025 13:31:18

whats-going-on-with-takeda-stock-on-friday
What's Going On With Takeda Stock On Friday?
08/22/2025 15:21:49

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to ...

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder
Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

takeda-pharma-maintains-outlook-even-as-vyvanse-generics-hit-sales
Takeda Pharma Maintains Outlook Even As Vy...
07/30/2025 20:04:11

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and ...

Core News & Articles
Earnings Scheduled For July 30, 2025
07/30/2025 08:32:48

takeda-reaffirms-fy2025-guidance-core-revenue-of-4530b-and-core-operating-profit-broadly-flat-at-1140b-core-eps-of-485
Takeda Reaffirms FY2025 Guidance, Core Rev...
07/30/2025 06:45:36

FY2025 Outlook (unchanged from May 2025)(Billion yen, except percentages and per share amounts)ItemFY2025 FORECASTFY2025 MANAGE...

takeda-pharmaceutical-q1-adj-epads-052-beats-047-estimate-sales-766b-beat-753b-estimate
Takeda Pharmaceutical Q1 Adj. EPADS $0.52 ...
07/30/2025 06:43:00

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0...

insights-ahead-takeda-pharmaceuticals-quarterly-earnings
Insights Ahead: Takeda Pharmaceutical's Qu...
07/29/2025 15:02:51

takeda-receives-fda-510k-clearance-for-hyhub-and-hyhub-duo-devices-for-patients-17-years-of-age-and-older-that-allow-hyqvia-to-be-transferred-from-vials-without-using-needle-in-home-environment-or-clinical-setting
Takeda Receives FDA 510(k) Clearance For H...
07/21/2025 12:09:21

HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA1First Devices Customized for a Plasma-Derived Therapy...

takedas-oveporexton-demonstrates-safety-and-efficacy-in-global-phase-3-studies-paving-way-for-new-narcolepsy-treatment
Takeda's Oveporexton Demonstrates Safety a...
07/14/2025 07:19:42

Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Sympto...

takeda-announces-fda-approval-of-gammagard-liquid-erc
Takeda Announces FDA Approval Of GAMMAGARD...
06/30/2025 12:05:16

takeda-gains-ec-approval-for-adcetris-in-combination-with-ecadd-chemotherapy-regimen-in-adult-patients-with-newly-diagnosed-stage-iib-with-risk-factorsiiiiv-hodgkin-lymphoma
Takeda Gains EC Approval For ADCETRIS In C...
06/03/2025 14:14:43

- Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma- ADCET...

Core News & Articles
Reported Sunday, Protagonist And Takeda Pr...
06/02/2025 07:42:12

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, signifi...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION